Cogent Biosciences Inc (COGT) financials
Cogent Biosciences revenue and earnings by year
Cogent Biosciences's revenue was $7.87 million in the fiscal year to December 31, 2020, down 65.0% from the year before. Net income was -$74.8 million, -950.4% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 5.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|
| Revenue | 8 | 22 | 10 | 8 | 6 |
| Revenue growth | -65.0% | 131.1% | 16.4% | 31.5% | — |
| Operating income | -82 | -32 | -36 | -26 | -19 |
| Operating margin | -1044.3% | -143.0% | -369.9% | -312.8% | -300.1% |
| Net income | -75 | -32 | -35 | -25 | -18 |
| Net margin | -950.4% | -141.5% | -354.8% | -304.9% | -285.2% |
| Diluted EPS | -$15.44 | -$4.20 | -$6.40 | -$10.00 | — |
| Free cash flow | -36 | -42 | -33 | -27 | -22 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open COGT in Markets.
See also: COGT returns
No forecast, no recommendation. This page describes Cogent Biosciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.